Despite physiological differences from mammals, the zebrafish model serves as a valuable predictive system for therapeutic response in cancer [9], with our data demonstrating its potential to guide patient stratification for DCPS inhibition therapy in AML based on DNMT3A, FLT3, and FHIT status. The gene discussed is DNMT3A; the disease is acute myeloid leukemia.